Clinical Trial Update: Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in patients with hematologic cancers undergoing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia Bcr-abl1 Positive
• Hodgkin Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndrome
• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• Cyclophosphamide (post-transplant) (cyclophosphamide)
• Fludarabine phosphate (Fludarabine phosphate)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Hematopoietic and Lymphoid Cell Neoplasm, High Risk Acute Myeloid Leukemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING